Mechelen, Belgium; 7 December 2010 - Galapagos NV (Euronext: GLPG) announced today a capital increase arising from employee warrant exercises.
Since its inception in 1999, Galapagos has used warrant plans to incentivize personnel and management and have them share in the success of the company. Following warrant exercises during the exercise period in November 2010, Galapagos issued 76,157 new ordinary shares on 7 December 2010 for a total capital increase (including issuance premium) of €663,257.30. No member of the Board or Executive Committee exercised warrants.
To date, Galapagos’ total share capital amounts to €142,590,770.44; the total number of securities conferring voting rights is 26,358,984, which is also the total number of voting rights (the “denominator”); all securities conferring voting rights and all voting rights are of the same category. The total number of rights (warrants) to subscribe to not yet issued securities which confer voting rights is 2,660,161, which is also the total number of voting rights that may result from the exercise of these warrants. Galapagos does not have outstanding any in voting securities convertible bonds nor shares without voting rights.
About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a mid-size biotechnology company specialized in the discovery and development of small molecule and antibody therapies with novel modes-of-action. The Company is progressing one of the largest pipelines in biotech, with six clinical and over 50 small molecule discovery/pre-clinical programs. Through risk/reward-sharing alliances with GlaxoSmithKline, Lilly, Janssen Pharmaceutica, Merck & Co., Roche and Servier, Galapagos is eligible to receive up to €3.3 billion in downstream milestones, plus royalties. The Galapagos Group has over 800 employees and operates facilities in seven countries, with global headquarters in Mechelen, Belgium. More info at: www.glpg.com
CONTACT
Elizabeth Goodwin, Director Investor Relations Tel: +31 6 2291 6240 ir@glpg.com
